Inactive Instrument

Propanc Biopharma Inc Share Price Other OTC

Equities

US74346N1072

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 559K 43.06M
Net income 2022 -2M -154M Net income 2023 -2M -154M EV / Sales 2022 -
Net Debt 2022 1.09M 84.36M Net Debt 2023 536K 41.31M EV / Sales 2023 -
P/E ratio 2022
-0.07 x
P/E ratio 2023
-0.08 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.78%
More Fundamentals * Assessed data
Dynamic Chart
Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office CI
Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC CI
Propanc Biopharma, Inc. Enters into and Closed a Loan Agreement with an Investor CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC CI
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding CI
More news
Managers TitleAgeSince
Chief Executive Officer 50 14/10/07
Founder 77 14/10/07
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 50 14/10/07
Founder 77 14/10/07
Director/Board Member 74 22/12/20
More insiders
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
More about the company